Inventor · disambiguated record
Diane Hollenbaugh
Also filed as: HOLLENBAUGH DIANE · HOLLENBAUGH DIANE L · HOLLENBAUGH DIANE LOUISE · SADRA ALI
25 granted patents·14 pending applications·1,309 citations·filing 1992–2024
97Inventor score
Files withBRISTOL MYERS SQUIBB CO11ABBVIE BIOTHERAPEUTICS INC8FIVE PRIME THERAPEUTICS INC6BONUM THERAPEUTICS INC3BOSCH ELIZABETH2
Top patents by PatentIndex Score
39 records- 0197US7678890B2Compositions and methods of treating disease with FGFR fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2006·Granted Mar 16, 2010·67 cites·3 claims
- 0297US5916560AMethods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewithBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Jun 29, 1999·175 cites·24 claims
- 0396US6051228AAntibodies against human CD40BRISTOL MYERS SQUIBB CO·Filed 1998·Granted Apr 18, 2000·202 cites·17 claims
- 0495US7982014B2FGFR3-IIIc fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2010·Granted Jul 19, 2011·24 cites·12 claims
- 0595US7214493B2Polynucleotides encoding humanized antibodies against human 4-1BBBRISTOL MYERS SQUIBB CO·Filed 2005·Granted May 8, 2007·130 cites·10 claims
- 0694US8580936B2Polynucleotides encoding FGFR1-IIIc ECD fusion proteinsWILLIAMS LEWIS T·Filed 2011·Granted Nov 12, 2013·40 cites·25 claims
- 0794US6887673B2Humanized antibodies against human 4-1BBBRISTOL MYERS SQUIBB CO·Filed 2003·Granted May 3, 2005·148 cites·5 claims
- 0893US8173134B2ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing themBOSCH ELIZABETH·Filed 2011·Granted May 8, 2012·24 cites·23 claims
- 0992US8598320B2Anti-PCSK9 and methods for treating lipid and cholesterol disordersHEDRICK JOSEPH A·Filed 2008·Granted Dec 3, 2013·52 cites·9 claims
- 1092US5540926ASoluble and its use in B cell stimulationBRISTOL MYERS SQUIBB CO·Filed 1992·Granted Jul 30, 1996·96 cites·18 claims
- 1191US5876950AMonoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapyBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Mar 2, 1999·115 cites·50 claims
- 1290US6312693B1Antibodies against human CD40Filed 1999·Granted Nov 6, 2001·68 cites·26 claims
- 1388US11642417B2Compositions of protein complexes and methods of use thereofBONUM THERAPEUTICS INC·Filed 2021·Granted May 9, 2023·2 cites·21 claims
- 1488US10023645B1Anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Jul 17, 2018·5 cites·11 claims
- 1587US5993800AMethods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligandBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Nov 30, 1999·93 cites·10 claims
- 1685US8501191B2FGFR2-IIIb fusion proteins and methods of making themBOSCH ELIZABETH·Filed 2012·Granted Aug 6, 2013·6 cites·18 claims
- 1779US6413514B1Methods of using antibodies against human CD40BRISTOL MYERS SQUIBB CO·Filed 1999·Granted Jul 2, 2002·35 cites·10 claims
- 1879US2022119542A1Anti-cd40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1978US10400041B2Nucleic acid molecules encoding anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Sep 3, 2019·1 cites·20 claims
- 2078US5945513AFusion proteins comprising gp39 and CD8BRISTOL MYERS SQUIBB CO·Filed 1996·Granted Aug 31, 1999·25 cites·2 claims
- 2177US10519243B2Anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Dec 31, 2019·1 cites·9 claims
- 2277US2021277137A1Anti-cd40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2374US2024390510A1Compositions of protein complexes and methods of use thereofBONUM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2474US2021024642A1Anti-cd40 antibody and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2573US10844131B2Anti-CD40 antibodyABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Nov 24, 2020·0 cites·9 claims
- 2672US12303567B2Compositions of protein complexes and methods of use thereofBONUM THERAPEUTICS INC·Filed 2023·Granted May 20, 2025·0 cites·19 claims
- 2772US10597460B2Anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Mar 24, 2020·0 cites·2 claims
- 2867US2009186037A1Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewithBRISTOL MYERS SQUIBB CO·Filed 2008·Application pending·0 cites
- 2966US9192683B2Methods of treating disease with FGFR1 fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2013·Granted Nov 24, 2015·0 cites·21 claims
- 3065US9173957B2FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIICFIVE PRIME THERAPEUTICS INC·Filed 2013·Granted Nov 3, 2015·0 cites·6 claims
- 3164US2017349643A1Compositions and methods of treating disease with fgfr fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3261US2024366776A1Compositions of protein complexes and methods of use thereofHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 3359US2016096876A1Compositions and methods of treating disease with fgfr fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 3457US2002031510A1Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewithBRISTOL MYERS SQUIBB CO·Filed 2001·Application pending·0 cites
- 3556US2005202011A1Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewithFiled 2005·Application pending·0 cites
- 3650US2014161798A1Anti-pcsk9 and methods for treating lipid and cholesterol disordersMERCK SHARP & DOHME·Filed 2013·Application pending·0 cites
- 3742US2011319324A1Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseasesLIN JUNYU·Filed 2010·Application pending·0 cites
- 3842US2007054851A1Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseasesLIN JUNYU·Filed 2006·Application pending·0 cites
- 3934US2002068346A1Modified inosine 5'-monophosphate dehydrogenase polypeptides and uses thereofFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →